MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorGezondheidszorg

30.59 -2.17

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.21

Max

31.35

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	198
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+72.46% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	346M 2B
Vorige openingsprijs	32.76
Vorige sluitingsprijs	30.59

Nieuwssentiment

By Acuity

100%

334 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 apr 2026, 22:56 UTC

Belangrijke Nieuwsgebeurtenissen

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 apr 2026, 20:50 UTC

Acquisities, Fusies, Overnames

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 apr 2026, 23:55 UTC

Marktinformatie

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 apr 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 apr 2026, 23:23 UTC

Belangrijke Nieuwsgebeurtenissen

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 apr 2026, 23:07 UTC

Winsten

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 apr 2026, 23:02 UTC

Belangrijke Nieuwsgebeurtenissen

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 apr 2026, 22:39 UTC

Winsten

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 apr 2026, 22:08 UTC

Marktinformatie

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 apr 2026, 21:56 UTC

Acquisities, Fusies, Overnames

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 apr 2026, 21:31 UTC

Belangrijke Nieuwsgebeurtenissen

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 apr 2026, 20:38 UTC

Winsten

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 apr 2026, 20:31 UTC

Acquisities, Fusies, Overnames

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 apr 2026, 20:16 UTC

Acquisities, Fusies, Overnames

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 apr 2026, 20:16 UTC

Acquisities, Fusies, Overnames

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 apr 2026, 20:13 UTC

Acquisities, Fusies, Overnames

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 apr 2026, 20:07 UTC

Marktinformatie

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 apr 2026, 20:07 UTC

Acquisities, Fusies, Overnames

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

72.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.91 USD 72.46%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.